NovoCure
NVCR
NVCR
360 hedge funds and large institutions have $17.2B invested in NovoCure in 2021 Q2 according to their latest regulatory filings, with 78 funds opening new positions, 124 increasing their positions, 114 reducing their positions, and 43 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
10% more funds holding
Funds holding: 326 → 360 (+34)
1.64% more ownership
Funds ownership: 73.49% → 75.13% (+1.6%)
9% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 114
Holders
360
Holding in Top 10
6
Calls
$775M
Puts
$246M
Top Buyers
| 1 | +$712M | |
| 2 | +$118M | |
| 3 | +$97M | |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$79M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$75.8M |
Top Sellers
| 1 | -$130M | |
| 2 | -$90.7M | |
| 3 | -$83.2M | |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$80.6M |
| 5 |
Two Sigma Investments
New York
|
-$71M |